1 Department of Oto-Rhino-Laryngology, University Hospital ... Afterwards the tissue was blocked and permeabilized with a solution of 10% normal horse serum (Merck, #H0146), 1% bovine serum albumin ...

On Thursday, Merck & Co Inc (NYSE:MRK) reported third-quarter sales of $16.66 billion, up 4% year over year, beating the consensus of $16.47 billion. Merck reported a decline of 11% in sales of ...

Merck's Q3 sales reached $16.7 billion, a 4% YoY increase, beating the $16.5 billion consensus estimate. Merck reported a decline of 11% in sales of Gardasil to $2.31 billion, a vaccine that ...

Its top-selling treatment, Keytruda, will lose patent protection in a few years. Then Merck will face biosimilar competition and likely see sales slide noticeably. There aren't any obvious ...

The Gardasil franchise is the company's second largest sales driver behind Keytruda, and Merck remains steadfast it can garner more than $11 billion from the key product in 2030. Fewer than 10% of ...

Merck (NYSE:MRK) beat Street forecasts with its Q3 2024 revenue on Thursday as its blockbuster cancer therapy Keytruda continued to drive sales growth while its human papillomavirus vaccine ...

Oct 31 (Reuters) - Merck & Co (MRK.N), opens new tab said on Thursday that weak sales of Gardasil in China are likely to carry over into 2025 as the vaccine's distributor there reduces inventories ...

This year, pharmaceutical giant Merck (NYSE: MRK) is it: The drugmaker's shares are down by 2% in 2024 while the broader S&P 500 is up by 21%. Even when we zoom out, Merck hasn't performed ...

With its portfolio of cancer medicines and one of the pharma industry's most recognizable names, it's no surprise that investors are curious about whether to buy shares of Merck (NYSE: MRK).